GLP-1 drugs: An economic disruptor? (2024)

Effectiveness and Lived Experience

• Many commenters using semaglutide/tirzepatide report dramatic appetite suppression, effortless calorie deficits, and large weight loss (tens of kilos) after years of failed diets.
• Common themes: forgetting to eat, feeling full very quickly, groceries and Starbucks spend dropping, alcohol becoming unappealing, and in some cases resolution of IBS‑like symptoms.
• Others report milder effects or none at all; some plateau and need dose escalation, some regain weight when stopping. Several frame GLP‑1s as “performance enhancers” for dieting rather than magic.

Side Effects, Long‑Term Risk, and Appropriate Use

• GI issues (nausea, vomiting, constipation, “food sitting” in the stomach) are frequent, especially during dose increases; a minority describe severe outcomes like gastroparesis or chronic nausea.
• Some insist long‑term safety is well‑supported by ~10 years of diabetes use; others argue that 20‑year horizons are needed and cite signals around stomach paralysis, pancreatitis, bone health, and mood.
• Strong disagreement over use in people who are only slightly overweight or at normal body fat; some see this as irresponsible given unknowns, others as legitimate personal choice.

Impulse Control Beyond Food

• Mixed reports: some users see broader reductions in impulsive behaviors (snacking, alcohol, other “compulsion substitution”); others say only food‑related urges change and they still shop, create, and pursue hobbies normally.
• Several commenters doubt there is solid evidence yet for generalized impulse control and warn against extrapolating from anecdotes.

Economic and Social Impact

• Debate over whether changes in malls, stadium concessions, and retail are GLP‑1‑driven versus longstanding trends (overbuilt US retail, e‑commerce, COVID corrections).
• Some expect real hits to junk food, soda, alcohol, and concession‑heavy business models; others think much of the “$100T disruption” narrative is overblown or mis-attributing existing shifts.
• Counter‑arguments note healthier, lighter people might spend more on other goods (bikes, clothes, wellness) and still incur healthcare costs as they live longer.

Cost, Access, and Inequality

• US prices are high; compounded versions briefly lowered costs but are being squeezed as official shortages end. Other countries report far cheaper access.
• Concerns that top earners will benefit first, potentially widening performance and promotion gaps; others expect generics and global manufacturing to make GLP‑1s cheap and widespread over time.

Ethical and Cultural Questions

• Tension between fixing “brain chemistry” vs fixing food systems, urban design, and sedentary lifestyles. Some liken GLP‑1s to treating societal problems with pills.
• Worries about a Brave New World–style future of chemically regulated workers versus enthusiasm from those whose lives are transformed by finally escaping compulsive eating.
• Many criticize the article’s style as hype‑driven “broetry,” with precise but unsourced stats and speculative chains of second‑order effects.